Company Overview - EyePoint Pharmaceuticals is a biotechnology company focused on innovative sustained-release drug delivery systems for ocular diseases, particularly chronic and severe retinal conditions [5] - The company generates revenue primarily through product sales and strategic collaborations, with a product pipeline that includes ILUVIEN, YUTIQ, DEXYCU, and EYP-1901 [8] - EyePoint's main customers are healthcare providers and ophthalmologists treating retinal conditions in the United States, China, and the United Kingdom [8] Financial Performance - As of the latest report, EyePoint's market capitalization is $1.1 billion, with a revenue of $31.37 million for the trailing twelve months (TTM) [4] - The company reported a net income loss of approximately $231.96 million (TTM) as it continues to invest heavily in research and development [4][9] - EyePoint ended the year with about $306 million in cash and investments, sufficient to fund operations into late 2027 [9] Recent Developments - Parkman Healthcare Partners disclosed a new position in EyePoint, acquiring 1,088,033 shares in the fourth quarter, which increased the position's value by $19.88 million [2] - EyePoint shares have surged by 93% over the past year, significantly outperforming the S&P 500's 20% gain during the same period [7] - The company is advancing DURAVYU, a sustained-release therapy for serious retinal diseases, with Phase 3 trials currently enrolling over 900 patients and topline data expected in mid-2026 [7] Market Position - EyePoint is positioned to compete in a large ophthalmology market, which is currently dominated by frequent anti-VEGF injections [9] - The company’s differentiated product pipeline and strategic alliances support its leadership in ophthalmic therapeutics [5]

Core Insights - Harrow's core growth drivers accelerated simultaneously in Q4 2025, with a goal to exceed $250 million in quarterly revenue by the end of 2027 [1] Financial Performance - Q4 2025 consolidated revenue was $89.1 million, a 33% increase year over year, while full-year revenue reached $272 million, up 36% compared to 2024 [5] - TRIESENCE revenue for Q4 was $5.1 million, a 36% increase from Q3, with full-year revenue at $9.9 million, marking a 193% increase versus 2024 [1] - IHEEZO Q4 revenue was $35.9 million, with full-year revenue of $81.3 million, reflecting 64% quarter-over-quarter growth and 65% year-over-year growth [2] Future Guidance - Management guided for 2026 full-year revenue between $350 million and $365 million, with adjusted EBITDA expected to be between $80 million and $100 million [3] - The company anticipates that 2026 will be more heavily weighted to the second half, with Q1 typically being the lowest due to various market dynamics [3] Cash Position - Harrow generated "just under" $44 million in cash from operations in 2025, ending the year with $72.9 million in cash and cash equivalents [4] Commercial Strategy - The company plans to increase SG&A expenses to approximately $185 million to $205 million in 2026, expanding sales forces for VEVYE and TRIESENCE, and preparing for the launches of BYOOVIZ and BYQLOVI [7] - Harrow aims to double the VEVYE sales force by Memorial Day, with a 115% increase in prescribers noted despite limited coverage in 2025 [8] Product Launches - Harrow expects to launch BYQLOVI in Q2 and BYOOVIZ in mid-2026, leveraging its existing retina team for the BYOOVIZ launch [13] Pipeline and Clinical Updates - G-MELT, a procedural sedation candidate, is on track for NDA submission in early 2027, with ongoing pharmacokinetic work and CMC activities [14] - Clinical trials for IHEEZO and TRIESENCE are underway, with data expected to support their market positions [15][16] Market Dynamics - IHEEZO's unit demand grew 56% year over year, with a significant portion of sales generated in the ASC setting [10] - Management is preparing for changes in IHEEZO's pass-through status, which may impact the ASC market [11]